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INTRODUCTION
Insulin resistance and hyperinsulinemia are associated with
hypertension, impaired glucose tolerance, obesity and dyslipi-
demia (1-4). These factors are also closely related to the devel-
opment of coronary heart disease. Hyperinsulinemia is char-
acterized by low high density lipoprotein (HDL)-cholesterol
and high low density lipoprotein (LDL)-cholesterol, which
causes coronary arteriosclerosis. This reflects the rate of mor-
tality due to cardiovascular diseases.
To date, euglycemic hyperinsulinemic clamp test has been
accepted as a standard test that measures insulin resistance
accurately (5). However, since euglycemic hyperinsulinemic
clamp test is very complex as well as requires skillful techni-
cians and many instrument, it has not been widely used in a
clinical setting. Alternately, homeostasis model assessment
(HOMA) index was designed to assess insulin resistance in
many patients, in which the concentrations of fasting insulin
and glucose are simply measured, and recently has been wide-
ly used (6, 7).
Considering that insulin resistance is the risk factor for coro-
nary heart disease, it may be closely related to the prognosis
of patients who underwent percutaneous coronary interven-
tion (PCI). To date, however, few studies have been conduct-
ed to examine whether insulin resistance is correlated with
the prognosis of patients who underwent PCI. Some studies
have reported that severe coronary angiographic findings and
stent restenosis were closely associated with insulin resistance
(8, 9).
Based on the assumption that insulin resistance is closely
associated with the complications after PCI or the prognosis
after PCI, we conducted a 30-day follow-up clinical study to
observe major adverse cardiac events (MACE) in patients who
underwent PCI.
MATERIALS AND METHODS
Subjects
In this study, we examined 98 consecutive patients with
chest pain who underwent diagnostic coronary angiography
between May and September 2004. We excluded patients
who were treated for diabetes mellitus; those who were newly
diagnosed as diabetes mellitus; those who had thyroid or ad-
renal insufficiency; those who underwent PCI for coronary
heart disease within a recent 6-month period; and those who
underwent primary PCI for acute myocardial infarction. The
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The Effect of Insulin Resistance on Prognosis of Non-Diabetic
Patients Who Underwent Percutaneous Coronary Intervention
Insulin resistance is an important risk factor for coronary artery disease. However,
there has been no data regarding its clinical effect on the outcomes of percutaneous
coronary intervention (PCI) in non-diabetic patients. We analyzed 98 non-diabetic
consecutive patients (59±11.5 yr, male:female=63:35) who underwent elective
coronary angiography. The patients were divided into two groups: Group I (n=71;
the value of HOMA-IR [homeostasis model assessment of insulin resistance] <2.6)
and Group II (n=27; the value of HOMA-IR ≥2.6). In-hospital and 30-day major
adverse cardiac events (MACE) were compared between the two groups. The con-
centrations of fasting insulin and triglyceride were significantly higher in Group II than
in Group I. Significant correlations were observed between the value of HOMA-IR
and body mass index (r=0.489, p<0.001), levels of total cholesterol (r=0.204, p=
0.045), triglyceride (r=0.334, p=0.001) and apolipoprotein B (r=0.212, p=0.038). PCI
was performed in 59 patients (60.2%). In-hospital and 30-day MACE were higher
in Group II than Group I (2.4% vs. 27.8%, p=0.008; 2.4% vs. 27.8%, p=0.008). Multi-
variate analysis revealed that the value of HOMA-IR ≥2.6 was an independent
predictor of MACE. Increased HOMA-IR level is an important prognostic indicator
in non-diabetic patients underwent PCI.
Key Words : Coronary Disease; Insulin; Prognosis; Angioplasty
Received : 15 June 2005
Accepted : 13 October 2005Insulin Resistance after Percutaneous Coronary Intervention 213
clinical diagnosis on admission was stable angina pectoris in
29.6% (29 patients) and unstable angina pectoris in 70.4%
(69 patients). On admission, patients were interviewed to
collect such data as the risk factors for coronary heart disease,
the personal history of smoking, diabetes mellitus and hyper-
tension, the family history and the past history of myocardial
infarction or stroke. All patients gave informed consent ac-
cording to a protocol approved by the Chonman National
University Hospital Ethics Committee.
Blood samples and neasurements
In our patients, samples were collected from venous blood
after overnight fasting, and blood chemistry was performed.
Fasting plasma glucose and insulin were measured. Then, the
following parameters were measured: 1) the concentrations
of serum lipid including total cholesterol, triglyceride, HDL-
cholesterol, LDL-cholesterol, Apolipoprotein AI (Apo AI),
Apolipoprotein B (Apo B) and lipoprotein (a) [Lp (a)]; 2)
leukocyte count, monocyte count, erythrocyte sedimentation
rate (ESR) and high-sensitivity C-reactive protein (hsCRP);
and 3) the concentrations of fibrinogen, fibrinogen degrada-
tion product (FDP) and homocysteine.
Insulin resistance was calculated by the homeostasis model
assessment of insulin resistance (HOMA-IR), proposed by
Mattews et al., whose formula was: HOMA-IR (mg/dL×U/
mL)=fasting glucose (mg/dL)×fasting insulin (U/mL)/405 (6).
To determine cut-off points of the HOMA-IR as predictors
of in-hospital and 30-day adverse cardiac events, receiver oper-
ating characteristics (ROC) analyses were performed. The area
under curve (AUC) of HOMA-IR was 0.738 (p=0.006). Cut-
off points of HOMA-IR for in-hospital and 30-day cardiac
events, determined by ROC analysis, were 2.56, 2.60, respec-
tively. Therefore, we used 2.6 as a cut-off point for the anal-
ysis in clinical usefulness. The cut-off point for in-hospital
and 30-day adverse cardiac events yielded sensitivities of 66.8
% and 77.9% and specificities of 68.2% and 70.2%, respec-
tively. Based on the cut-off value of 2.6, therefore, we divid-
ed patients into Group I (the value of HOMA-IR <2.6) and
Group II (the value of HOMA-IR ≥2.6).
Coronary angiography and intervention
We accessed left or right femoral artery by the Seldinger
method or accessed radial artery, and performed coronary an-
giography using the Judkins method. Coronary angiographic
findings were interpreted by two examiners who were blinded
to patients’ profile of insulin resistance. Significant stenosis
was defined as a luminal narrowing of 50% or greater (10).
PCI was performed according to current clinical practice at
physician’s discretion. Stenting was performed in cases whom
percutaneous balloon dilatation produced suboptimal results
that the residual stenosis was more than 30%, and the dissec-
tion was developed (11, 12). On diagnostic coronary angio-
graphy, the patency of the treated artery was evaluated by
the Thrombolysis In Myocardial Infarction (TIMI) score. Suc-
cessful reperfusion following PCI was defined as TIMI III
flow with <25% residual stenosis (13).
In all patients, aspirin (300 mg/day) and clopidogrel (150
mg/day) were loaded or aspirin (100 mg daily) and clopido-
grel (75 mg daily) started >3 days before procedure. An intra-
venous bolus of 5,000 U of unfractionated heparin was given,
and then additional heparin boluses were given to maintain
activated clotting time >300 sec during procedure. Aspirin
(100 mg/day) and clopidogrel (75 mg/daily for 30 days) were
prescribed to all patients after procedure.
In-hospital adverse outcomes were defined as the overall
procedure was not successfully done since coronary wire or
balloon catheter could not pass through the lesion; myocardial
infarction was developed following PCI; patients underwent
repeated PCI or emergent coronary artery bypass graft (CABG)
surgery for target vessel revascularization (TVR). Myocardial
infarction was defined as a CK-MB elevation greater than
three times the upper normal limit or a new change of EKG
findings. Between Group I and II, we compared MACE such
as death, myocardial infarction and target vessel revasculariza-
tion during a 30-day period.
Statistical analysis
Statistical analysis was done using SPSS
� Ver.12.0 for Win-
dows. All data were represented as mean±standard deviation.
Intergroup analysis was done using independent t-test and
2 test, and intragroup analysis was done using paired t-test.
Multivariate analysis was done to determine the factors relat-
ed to MACE. Spearman correlation was used to examine the
relationship between HOMA-IR and other laboratory find-
ings. Statistical significance was set at p<0.05.
RESULTS
In studied patients, the mean age was 59.8±11.5 yr and
a male-to-female ratio was 1.8:1. The mean value of HOMA-
IR was 2.3±1.69, and 71 patients were into Group I (the
value of HOMA-IR<2.6) and 27 patients into Group II (the
value of HOMA-IR≥2.6). Between Group I and II, there were
no significant differences in cardiovascular risk factors includ-
ing hypertension, diabetes mellitus and smoking (Table 1).
The concentrations of fasting plasma glucose were 101.2±
13.89 mg/dL in Group I and 108.4±9.79 mg/dL in Group
II, and those of fasting insulin were 11.9±4.99 U/mL  in
Group I and 31.8±14.23  U/mL in Group II (Table 2). The
concentration of triglyceride was significantly higher in Group
II than in Group I (151.4±192.43 mg/dL vs. 94.5±62.86
mg/dL, p=0.028). HOMA-IR was correlated with body mass
index (r=0.489, p<0.001), levels of total cholesterol (r=0.204,
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tein B (r=0.212, p=0.038).
Coronary angiography revealed the presence of significant
stenosis in 64 patients (Group I; 43 patients, Group II; 21
patients). There was no significant differences in the preva-
lence of multi-vessel disease between the two groups (p=
0.164). The lesion locations were left anterior descending
artery (LAD) in 72.1%, left circumflex artery (LCX) in 16.3%
and right coronary artery (RCA) in 11.6% of Group I; and
LAD in 47.6%, LCX in 19.0% and RCA in 33.3% of Group
II (p=0.085). According to the American College of Cardiol-
ogy and American Heart Association (ACC/AHA) classifica-
tion, Type B1 was demonstrated in 44.2%, Type B2 in 34.9%
and Type C in 20.9% of Group I; and Type B1 in 28.6%,
Type B2 in 33.3% and Type C in 33.3% of Group II (p=
0.283). Preprocedural TIMI flow grades were grade 0 in 16.3
%, grade I in 7.0%, grade II in 9.3% and grade III in 67.4%
of Group I; and grade 0 in 19.0%, grade I in 9.5%, grade II
in 19.0% and grade III in 52.5% of Group II (p=0.623).
In 59 patients, PCI was performed with an angiographic
success rate of 94.9% (Table 3). The procedural failure due
to crossing failure of guide wire or balloon catheter occurred
in no patient (0.0%) of Group I and 2 patients (11.1%) of
Group II. Procedure-related complications included one case
of myocardial infarction (2.4%) in Group I; and two cases of
myocardial infarction (11.1%), one case of emergent CABG
(5.6%) in Group II. The procedure-related complications were
more prevalent in Group II than Group I (p=0.008). The
MACE at 30-day follow-up was 1 case (2.4%) of TVR in
Group I and 4 cases (22.2%) of TVR in Group II, and the
incidence of MACE was significantly higher in Group I than
Group II (p=0.008).
PCI, percutaneous coronary intervention; MI, myocardial infarction; BMI,
body mass index.
Group I (n=71) Group II (n=27) p value
Age (yr) 58±12.1 61±10.7 0.708
Male (%) 44 (62.0) 19 (70.4) 0.488
Hypertension (%) 23 (32.4) 11 (40.7) 0.481
Dyslipidemia (%) 23 (32.4) 11 (40.7) 0.348
Smoker (%) 20 (28.2) 5 (18.5) 0.239
Family history (%) 8 (11.3) 3 (11.1) 0.645
Previous MI (%) 4 (5.6) 0 (0.0) 0.269
Previous PCI (%) 4 (5.6) 3 (11.1) 0.294
Ejection fraction (%) 64.4±10.39 63.7±10.18 0.079
BMI (kg/m
2) 23.9±2.41 26.4±3.09 0.116
Clinical diagnosis on admission (%) 0.187
Stable angina 22 (31.0) 7 (25.9)
Unstable angina 49 (69.0) 21 (74.1)
Table 1. Baseline clinical characteristics of Group I (the value of
HOMA-IR [homeostasis model assessment of insulin resistance]
<2.6) and Group II (the value of HOMA-IR ≥2.6)
Hb, hemoglobin; HOMA-IR, homeostasis model assessment of insulin
resistance; hsCRP, high-sensitivity C-reactive protein; HDL, high densi-
ty lipoprotein; LDL, low density lipoprotein.
Group I (n=71) Group II (n=27) p value
Laboratory findings
Fasting glucose (mg/dL) 101.2±13.89 108.4±9.79 0.072
Fasting insulin ( U/mL) 11.9±4.99 31.8±14.23 <0.001
HbA1c (%) 5.6±0.38 5.8±0.34 0.404
HOMA-IR 1.4±0.51 4.4±1.82 <0.001
Monocyte (×10
3) 443.8±223.75 558.1±305.54 0.364
hsCRP (mg/dL) 1.0±3.11 0.8±1.84 0.431
Total cholesterol (mg/dL) 188.9±34.00 189.9±35.33 0.643
Triglyceride (mg/dL) 96.5±62.86 151.4±192.43 0.028
HDL-cholesterol (mg/dL) 50.3±13.19 48.3±14.67 0.755
LDL-cholesterol (mg/dL) 124.9±33.68 121.7±34.31 0.872
Lipoprotein (a) (mg/dL) 27.3±19.53 29.7±21.12 0.415
Apolipoprotein AI (mg/dL) 125.1±27.29 121.8±25.68 0.805
Apolipoprotein B (mg/dL) 98.6±22.70 98.2±23.23 0.621
Homocysteine (mg/dL) 9.6±3.95 9.9±4.45 0.945
Fibrinogen (mg/dL) 264.8±72.01 253.7±71.78 0.671
Coronary angiographic findings 0.164
No significant stenosis (%) 28 (39.4) 6 (22.2)
Single vessel disease (%) 28 (39.4) 11 (40.7)
Multivessel disease (%) 15 (21.1) 10 (37.0)
Table 2. Laboratory and coronary angiographic findings 
PTCA, percutaneous transluminal coronary angioplasty; MI, myocardial
infarction; ULN, upper limit of normal; CABG, coronary artery bypass
graft; TVR, target vessel revascularization.
Group I  Group II  p value
(n=41) (n=18)
In-hospital PCI-related complication (%) 0.008
PCI failure 0 (0) 2 (11.1)
Death 0 (0) 0 (0)
MI 0 (0) 1 (5.6)
CK-MB rise >5× ULN 1 (2.4) 1 (5.6)
Emergent CABG 0 (0) 1 (5.6)
Repeated PCI 0 (0) 0 (0)
Cumulative 30 day MACE (%) 0.008
Death 0 (0) 0 (0)
MI 0 (0) 1 (5.6)
TVR 1 (2.4) 4 (22.2)
Total 1 (2.4) 5 (27.8)
Table 3. The incidences of in-hospital and 30-day major adverse
cardiac events
HOMA-IR, homeostasis model assessment of insulin resistance; TIMI,
Thrombolysis in myocardial infarction; ACC/AHA, American College of
Cardiology/American Heart Association.
Variables Odds ratio 95% CI p value
HOMA ≥2.6 49.27 1.05-231.13 0.048
Fasting glucose ≥110 mg/dL 4.58 0.28-83.98 0.277
Fasting insulin ≥20 U/mL 78.54 0.25-251-32 0.138
Preprocedural TIMI flow <3 5.35 0.08-34.69 0.431
ACC/AHA lesion type B2, C 1.29 0.02-66.03 0.899
Age > 65 yr 3.25 0.07-140.38 0.539
Multivessel disease 3.17 1.00-104.88 0.518
Dyslipidemia 5.89 0.17-204.55 0.327
Table 4. Independent predictors for 30-day major adverse car-
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Multivariate analysis revealed that the value of HOMA-IR
≥2.6 was the independent prognostic indicators for MACE
(p=0.048) (Table 4).
DISCUSSION
Our clinical study indicated that high HOMA-IR value is
related with the high incidence of complications and short-
term major adverse cardiac events (MACE) following PCI
even in non-diabetic patients.
Insulin resistance plays a crucial role in the development of
metabolic disorder accompanied by obesity, dyslipidemia, dia-
betes mellitus, impaired glucose tolerance and hypertension;
and is also closely related to the incidence of cardiovascular
disease (14-22). Hyperinsulinemia is an only indirect indica-
tor for insulin sensitivity. Several large-scale studies have re-
vealed that hyperinsulinemia is closely associated with the
mortality due to cardiovascular disease (14, 21, 23). To date,
however, few large-scale studies have been conducted to exam-
ine the relationship between insulin resistance and coronary
heart disease (24, 25). Recently, IRAS (insulin resistance
atheroscleorsis study) group has conducted large-scale epi-
demiologic studies, and has reported that insulin resistance
rather than insulin concentration is an independent, power-
ful risk factor for coronary heart disease (26). 
The mechanism by which insulin resistance provokes car-
diovascular disease is mainly associated with the development
of metabolic syndrome. It is well established that non-diabet-
ic patients with insulin resistance exhibits high concentration
of serum triglyceride, hypertension and low concentration of
HDL-cholesterol (1, 4, 23, 24). In recent years, among several
types of apolipoprotein that determines the conformational
stability and the metabolic direction of lipoprotein, apolipop-
rotein B has been elevated particularly in patients with insulin
resistance (27, 28). This has indicated that apolipoprotein B
is associated with the development of cardiovascular disease.
In addition, insulin resistance has been reported to reduce
flow-mediated vasodilation (FMD) of brachial artery, and to
thereby trigger the endothelial dysfunction (20). The present
study has shown that the value of HOMA-IR was correlated
with levels of triglyceride and inversely correlated with that
of HDL-cholesterol, which is similar to the results of previous
studies (1, 23, 24).
To date, only few studies based on coronary angiography
have examined the relationship between insulin resistance
and coronary atherosclerosis (8, 24, 25). According to Takeza-
ko et al., the profile of insulin resistance based on HOMA-IR
model was correlated with severity of coronary atherosclero-
sis based on Gensini’s score (8). Other studies have reported
that the incidence of MACE following PCI was higher in non-
diabetic patients with high concentration of HbA1c than
those with low concentration of HbA1c, although these stud-
ies did not evaluate using insulin resistance (29). Here, the
concentration of HbA1c was lower in non-diabetic patients
than in diabetic patients although it was ‘high’. On the other
hand, some studies have reported that hyperinsulinemia and
insulin resistance measured by HOMA are closely associated
with restenosis following stenting in non-diabetic patients
(9, 30). In our series, we have predicted that since insulin re-
sistance is the risk factor for coronary atherosclerosis and is
associated with the mortality due to cardiovascular disease, it
will affect the prognosis following PCI. As predicted, the re-
sults were that the higher value of HOMA-IR was associated
with the higher incidence of MACE, since more TVR was
performed in cases with higher value of HOMA-IR. Although
our results were based on non-diabetic patients, these findings
suggested that patients with high insulin resistance exhibited
high incidences of complex and heavy calcified lesions, com-
monly noted in coronary artery of patients with diabetes melli-
tus. Henceforth, comparative studies will be conducted regard-
ing this matter between diabetic and non-diabetic patients.
The limitation of present study has disclosed that it exam-
ined the small number of patients within a short period of
time. To date, however, few studies have been conducted to
examine whether insulin resistance is correlated with the
prognosis following PCI. For this reason, the present study
has its own value that it is a preliminary study for further
large-scale studies. Moreover, the present study failed to tes-
tify the reproducibility since it did not measure the value of
HOMA-IR in a repetitive manner during the period of ad-
mission. The concentrations of serum glucose and insulin can
be altered at each different measuring time, although the pre-
sent study measured them only once in the morning that
diagnostic coronary angiogram was performed. However,
HOMA-IR index is well reflected in euglycemic hyperinsu-
linemic clamp test, a standard test, and the clinical useful-
ness has been well established.
In conclusion, insulin resistance is associated with poor
prognosis in non-diabetic patients after PCI. However, long-
term large clinical follow-up studies should be conducted in
diabetic and non-diabetic patients. 
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